Electronic Study for Anastrozole Pharmacovigilance Evaluation

Electronic Study for Anastrozole Pharmacovigilance Evaluation

Collecting information regarding adverse events from patients on treatment with anastrazole with early stage breast cancer

Inclusion Criteria:

• Post-menopausal Early Invasive Breast Cancer Patients who are under anastrazole treatment, who have normal renal and hepatic functions.

Exclusion Criteria:

• Metastatic breast cancer patients, previous hormonal therapy, other malignancies.